ES2078654T3 - Analogos de atp. - Google Patents

Analogos de atp.

Info

Publication number
ES2078654T3
ES2078654T3 ES92302927T ES92302927T ES2078654T3 ES 2078654 T3 ES2078654 T3 ES 2078654T3 ES 92302927 T ES92302927 T ES 92302927T ES 92302927 T ES92302927 T ES 92302927T ES 2078654 T3 ES2078654 T3 ES 2078654T3
Authority
ES
Spain
Prior art keywords
formula
compound
salts
defined above
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92302927T
Other languages
English (en)
Inventor
Anthony Howard Ingall
Peter Alan Cage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra Pharmaceuticals Ltd
Astra USA Inc
Original Assignee
Astra Pharmaceuticals Ltd
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919107236A external-priority patent/GB9107236D0/en
Priority claimed from GB919123671A external-priority patent/GB9123671D0/en
Application filed by Astra Pharmaceuticals Ltd, Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2078654T3 publication Critical patent/ES2078654T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3821—Acyclic saturated acids which can have further substituents on alkyl substituted by B, Si, P or a metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicinal Preparation (AREA)
  • Color Television Image Signal Generators (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para la producción de un compuesto de la fórmula I en la que Q representa CR 1 R 2 , R representa O o CR 3 R 4 , W representa O o CH2, R 1 , R 2 , R 3 y R 4 representan independientemente hidrógeno o halógeno, X representa S(O)nR 5 , n representa 0,1ó 2, R 5 representa etilo, butilo o propilo, Y representa NH2 o alcoxiC1-6, y Z representa una porción ácida, además: a) cuando R representa CR 3 R 4 , entonces Q Z pueden representar hidroxi o OP(O)(OH)2; y b) cuando R y W representan O, Q representa CCl2 o CBr2, Y representa NH2 y Z representa P(O)(OH)2, entonces X puede representar S pentilo; o una de sus sales farmacéuticamente aceptable, cuyo proceso comprende: a) producir un compuesto de la fórmula I en el que R representa O o una de sus sales, haciendo reaccionar un compuesto de la fórmula II o una de sus sales donde W, X e Y son como se ha definido anteriormente y L1 representa un grupo lábil con un compuesto de la fórmula III o una de sus sales, O k Z -Q -P-OH j OH IIIdonde Z y Q son como se ha definido anteriormente; b) producir un compuesto de la fórmula I en la que R representa CR 3 R 4 , o una de sus sales, haciendo reaccionar un compuesto de la fórmula IV o una de sus sales, donde W, X e Y son como se ha definido anteriormente y L2 representa un grupo lábil con un compuesto de la fórmula V o una de sus sales, O O k k Z -Q -P -CR 3 R 4 -P OH j j OH OH V donde Z, Q, R 3 y R 4 son como se ha definido anteriormente; c) producir un compuesto de la fórmula I en el que R es CR 3 R 4 y Q Z es OP(O)(OH)2, o una de sus sales, haciendo reaccionar un compuesto de la fórmula I en la que Q Z es hidroxi con un compuesto de la fórmula VI o una de sus sales O k L3 -P OH j OH VI donde L3 es un grupo lábil; y d) separación de un grupo protector de un compuesto correspondiente protegido de la fórmula I en la que uno o más de los grupos funcionales está protegido, y cuando se desee o sea necesario convertir el compuesto resultante de la fórmula I u otra sal del mismo enuna de sus sales farmacéuticamente aceptable o viceversa.
ES92302927T 1991-04-06 1992-04-02 Analogos de atp. Expired - Lifetime ES2078654T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919107236A GB9107236D0 (en) 1991-04-06 1991-04-06 Compounds
GB919123671A GB9123671D0 (en) 1991-11-07 1991-11-07 Compounds

Publications (1)

Publication Number Publication Date
ES2078654T3 true ES2078654T3 (es) 1995-12-16

Family

ID=26298696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92302927T Expired - Lifetime ES2078654T3 (es) 1991-04-06 1992-04-02 Analogos de atp.

Country Status (18)

Country Link
EP (2) EP0579643A1 (es)
JP (1) JP3141028B2 (es)
CN (2) CN1031879C (es)
AT (1) ATE127808T1 (es)
CA (1) CA2107667A1 (es)
DE (1) DE69204717T2 (es)
DK (1) DK0508687T3 (es)
ES (1) ES2078654T3 (es)
FI (1) FI934366A7 (es)
GR (1) GR3018307T3 (es)
HU (2) HUT64967A (es)
IE (1) IE921091A1 (es)
IL (1) IL101485A0 (es)
MX (1) MX9201577A (es)
NO (1) NO933555D0 (es)
NZ (1) NZ242243A (es)
PL (1) PL297372A1 (es)
WO (1) WO1992017488A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5760021A (en) * 1992-05-29 1998-06-02 The Procter & Gamble Company Phosphonocarboxylate compounds pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
FR2721929B1 (fr) * 1994-06-30 1996-12-20 Centre Nat Rech Scient Analogues stables, non hydrolysables, de diphosphates et leurs procedes de preparation
AU5584698A (en) * 1996-10-30 1998-05-22 University Of North Carolina At Chapel Hill, The P2y receptor antagonists
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6667306B1 (en) 1998-01-15 2003-12-23 Millennium Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6440948B1 (en) * 1999-06-22 2002-08-27 Cv Therapeutics, Inc. Thiophene A2A receptor agonists
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
SE0401001D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
JP6577165B2 (ja) * 2011-01-26 2019-09-18 北京康倍得医▲藥▼技▲術▼▲開▼▲發▼有限公司 リボフラノシルプリン化合物、その調製方法、およびその使用
CN102659691B (zh) * 2012-05-23 2014-04-02 山东诚创医药技术开发有限公司 一种4,6-二氯-5-氨基-2-丙硫基嘧啶的制备方法
CN103288748A (zh) * 2013-06-21 2013-09-11 四川铂瑞生物医药有限公司 一种4.6-二氯-5-氨基-2-丙硫基嘧啶的制备方法
CN104003943A (zh) * 2014-05-06 2014-08-27 南通常佑药业科技有限公司 一种替格瑞洛中间体的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011080A1 (en) * 1989-03-24 1990-10-04 Daiichi Pharmaceutical Co., Ltd. Drug for improving brain function

Also Published As

Publication number Publication date
NO933555L (no) 1993-10-05
NZ242243A (en) 1993-06-25
MX9201577A (es) 1992-10-01
JPH06505987A (ja) 1994-07-07
EP0579643A1 (en) 1994-01-26
AU1451992A (en) 1992-11-02
IE921091A1 (en) 1992-10-07
HU9302812D0 (en) 1993-12-28
FI934366L (fi) 1993-10-05
GR3018307T3 (en) 1996-03-31
IL101485A0 (en) 1992-12-30
CN1120936A (zh) 1996-04-24
FI934366A0 (fi) 1993-10-05
DK0508687T3 (da) 1996-02-05
HU211334A9 (en) 1995-11-28
CN1068574A (zh) 1993-02-03
DE69204717T2 (de) 1996-04-25
CN1031879C (zh) 1996-05-29
PL297372A1 (en) 1993-09-06
AU648885B2 (en) 1994-05-05
EP0508687B1 (en) 1995-09-13
HUT64967A (en) 1994-03-28
DE69204717D1 (de) 1995-10-19
NO933555D0 (no) 1993-10-05
JP3141028B2 (ja) 2001-03-05
EP0508687A1 (en) 1992-10-14
CA2107667A1 (en) 1992-10-07
FI934366A7 (fi) 1993-10-05
WO1992017488A1 (en) 1992-10-15
ATE127808T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
ES2032749T3 (es) Acidos oxoftalazinil-aceticos heterociclicos.
LV10456A (lv) Triazolpiridazina atvasinajumi to iegusanas panemiens un pielietojums
ES2068601T3 (es) Metodo para producir nuevos analogos de vitamina d.
ATE40994T1 (de) L-n-n-propylpipekolsaeure-2,6-xylidid und dessen herstellung.
DK0508687T3 (da) ATP-analoger
AR245933A1 (es) Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales.
ES327312A1 (es) Procedimiento para la produccion de nuevos derivados de benzotiofeno.
ES2040856T3 (es) Un procedimiento para preparar un compuesto de tiofeno.
ES2063465T3 (es) Nuevos derivados n-sustituidos de alfa-mercapto-alquilaminas, su procedimiento de preparacion y los productos intermedios obtenidos, su aplicacion como medicamentos y composiciones que los contienen.
GB1159340A (en) Thion- and Thiol-Carbamate Derivatives
ES474232A1 (es) Un metodo para producir 2,6-diaminonebularinas
ES8105721A1 (es) Un procedimiento para la preparacion de nuevos 1, 2, 4-tria-zoles.
DE69906025D1 (de) Verfahren zur Lagerstabilisierung von Verbindungen mit Oxetan Ringen
ES8504778A1 (es) Un procedimiento para la preparacion de derivados de fenil-piperazina
ZA91288B (en) Coating compound,process for its production as well as use thereof
BG48694A3 (en) Method for preparing alkandiol- dicarboxilates
DE1445100A1 (de) Verfahren zur Herstellung 3-substituierter 3-Pyrrolidinole
ES8507527A1 (es) Procedimiento para producir derivados de tiatriazina
US3334115A (en) Basically substituted ureas and salts thereof
ES460705A1 (es) Un procedimiento para la preparacion de nuevos derivados de acido pirrol-1-carboxilico
US3342835A (en) Novel preparation of 2-imino-1, 3-dithiolanes and 2-imino-1, 3-dithianes
ES8506724A1 (es) Un procedimiento para la preparacion de bis esteres de acidos 1,4-ciclohexanodicarboxilicos y acidos alcanodicarboxilicos.
NO920619L (no) Oxazinobenzazolforbindelser
DE2365999A1 (de) Cyclopentane zur herstellung von 15-substituierten-omega-pentanorprostaglandinen
MY101765A (en) Benzopyran derivatives, compositions containing them and processes for their production

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 508687

Country of ref document: ES